MSN Laboratories has launched posaconazole in India under the brand name PosaOne as 100 mg delayed release tablets & 300 mg injections respectively. Posaconazole is a triazole antifungal agent indicated for treating mucormycosis patients.

Many patients recovering from Covid-19 have been detected with a rare and deadly fungal infection known as mucormycosis or black fungus. With mortality rates on the incline, accessibility of anti-fungal medication is being an unmet deficit in this testing times.

As an outcome of MSN’s competence in research and manufacturing of anti fungal infection drugs, it is now targeting to pro-actively reach to patients across India by ensuring the access of PosaOne, through its strong distribution network & field force, said the company.

The Hyderabad-based pharma major developed the active pharmaceutical ingredient (API) and the formulation of PosaOne in its in-house R&D and manufacturing units. The drug is approved by the Drug Controller General of India (DGCI) and matches to the International quality standards. As part of the Covid treatment range, MSN has already launched Favilow (favipiravir) in the strengths of 200mg, 400mg & 800mg, Oselow (Oseltamivir) as 75 mg capsules and also licensed Baridoz (baricitinib) recently with Eli Lilly.